AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2025
Feb 4, 2025
30849_dirs_2025-02-04_7e3af205-e0e8-46dd-b68a-1075ace1cd0b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2025-02-01
Reporting Person: Lee Jennifer Kayden (EVP, Head of North America)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-01 | Common Stock | M | 4513 | — | Acquired | 5485 | Direct |
| 2025-02-04 | Common Stock | S | 1447 | $59.43 | Disposed | 4038 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-01 | Restricted Stock Units | $ | M | 4513 | Disposed | Common Stock (4513) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.